It also appeared to decrease the protein levels of MCL-1and phospho-Akt in both tumor types although only the reduction of those proteins in A549shHTATIP2 tumors reached statistical significance (p < 0.05 for MCL-1, and p < 0.01 for phospho-Akt), suggesting that the response of A549 and A549shHTATIP2 tumors to sorafenib treatment involves the same set of signaling pathways that are affected to a different extent (Figure 6A,B and Figure S2). This evidence concerns the gene MCL1 and neoplasm.